JNTU B.Pharmacy IV COMPUTER AIDED DRUG DESIGN Previous Question Paper (July/August-2022 - R17)

The drug discovery and development process is a long, complex, and costly journey typically spanning 10-15 years. It proceeds through the following key stages:

1. Target Identification and Validation: Scientists identify a biological target (e.g., protein, enzyme, receptor) associated with a disease. Validation confirms that modulating this target will produce a therapeutic effect.
2. Lead Discovery: High-throughput screening (HTS) or structure-based design is used to identify 'lead' compounds that interact with the target.
3. Lead Optimization: The lead compound is modified to improve its potency, selectivity, pharmacokinetic properties (ADME), and reduce toxicity to create a 'drug candidate'.
4. Preclinical Development: In vitro and in vivo studies are conducted to assess safety, toxicity, and efficacy in animals before human exposure.
5. Clinical Trials: The candidate enters human testing in three phases: Phase I (safety and dosage in healthy volunteers), Phase II (efficacy and side effects in patients), and Phase III (large-scale confirmation of efficacy and safety).
6. Regulatory Approval and Post-Marketing Surveillance: After successful trials, the drug is submitted to regulatory bodies (like FDA/CDSCO) for approval. Phase IV monitoring continues after the drug is on the market to detect long-term side effects.

Bioisosterism refers to the replacement of an atom or group of atoms in a drug molecule with another atom or group that possesses similar physical or chemical properties, which produces broadly similar biological effects. This strategy is used to optimize potency, reduce toxicity, or improve metabolic stability.

Bioisosteres are classified into two main types:

1. Classical Bioisosteres: These involve atoms or groups with similar electronic and steric configurations. Examples include monovalent atoms (e.g., -F, -OH, -NH2, -CH3) or divalent groups (e.g., -CH2-, -NH-, -O-, -S-). For instance, replacing a hydrogen atom with a fluorine atom can block metabolic oxidation.
2. Non-classical Bioisosteres: These do not follow the strict steric or electronic rules of classical bioisosteres but produce similar biological responses. Examples include ring-chain transformations or the replacement of functional groups. A classic example is the replacement of a carboxylic acid group (-COOH) with a tetrazole ring, which maintains acidic properties while improving membrane permeability.